Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Avapritinib: First Approval.

Drugs - 1 Mar 2020

Dhillon Sohita

Abstract excerpt

Avapritinib (AYVAKIT™) is a potent and selective tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation loop mutants. It is being developed by Blueprint Medicines for the treatment of gastrointestinal stromal tumours (GIST), solid tumours and systemic mastocytosis. Avapritinib is approved in the USA for PDGFRA exon 18 (including D842V) mutant GIST and is undergoing...

Topics

Join the communities discussing this publication.

Drug Approval
Gastrointestinal Stromal Tumors
Mutation
Protein Kinase Inhibitors
Pyrazoles
Pyrroles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Receptor, Platelet-Derived Growth Factor alpha

Source

Identifiers

PMID: 32100250
DOI: 10.1007/s40265-020-01275-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Avapritinib: First Approval.PMID 32100250Read ↗

Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy.Semantic proximity Read ↗

The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutation.Semantic proximity Read ↗

Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.Semantic proximity Read ↗

Avapritinib for metastatic or unresectable gastrointestinal stromal tumors.Semantic proximity Read ↗

Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain.Semantic proximity Read ↗

Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study.Semantic proximity Read ↗

Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.Semantic proximity Read ↗

Emerging drugs for the treatment of gastrointestinal stromal tumors.Semantic proximity Read ↗

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.Semantic proximity Read ↗

The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST)Semantic proximity Read ↗

Avapritinib for advanced systemic mastocytosis.Semantic proximity Read ↗

An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.